Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City on Thursday, February 27, 2025.

As part of the event, David Moatazedi, President and CEO of Evolus, will host a fireside chat on Thursday, February 27, 2025, from 9:30 AM – 10:00 AM ET. A live webcast of the fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will remain available for 90 days following the event.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse is a trademark of Evolus, Inc.

Contacts

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com

Media:

Email: media@evolus.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  235.97
-1.61 (-0.68%)
AAPL  273.31
+0.36 (0.13%)
AMD  245.58
-2.38 (-0.96%)
BAC  52.27
-0.59 (-1.13%)
GOOG  276.64
-2.48 (-0.89%)
META  607.59
-2.30 (-0.38%)
MSFT  505.71
+2.42 (0.48%)
NVDA  186.59
-0.27 (-0.14%)
ORCL  217.03
-0.53 (-0.25%)
TSLA  398.10
-3.89 (-0.97%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.